Page 4 - SLIDES

Agenda

• Combination immunotherapy strategies:

• LBA24 COSMIC-021(N. Agarwal): Cabozantinib (C) in combination with

atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate

cancer (mCRPC): results of expanded cohort 6 of the COSMIC-021 Study

• Abst. 5770 PRINCE – pembro/Lu-PSMA discussed by Dr. Niazi

• Abst. 579MO 9KD-A2 – nivolumab/rucaparib discussed by Dr. Kokorovic

• ”Novel” AR antagonism strategies

• LBA26 SAKK 08/16 (R. Cathomas) Darolutamide maintenance in metastatic

castration resistant prostate cancer (mCRPC) previously treated with novel

hormonal agents (NHA) and non-progressive disease after subsequent treatment

with a taxane: A randomized double-blind placebo-controlled phase II trial

• Abst. 578MO (M. Markowski) Phase 1b/2 study of sabizabulin (VERU-111), an

androgen receptor transport disruptor, in men with metastatic castration resistant

prostate cancer (mCRPC) who failed an androgen receptor targeting agent

(ARTA)